Cenk SUNU, Yakup TOMAK, Mehmet KÖROĞLU, Oğuz KARABAY, Yasin KALPAKÇI, İlhan HACIBEKİROĞLU, Ahmet Cihad GENÇ, Tuba HACIBEKİROĞLU, Adem SARICAOĞLU

Efficacy of convalescent plasma according to blood groups in COVID-19 patients

Background/aim: In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the treatment of critically ill patients diagnosed with COVID-19. Materials and methods: Twenty-eight critically ill and laboratory-confirmed COVID-19 patients who were admitted to the intensive care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups: patients who received anti-A antibody (Ab) containing CP (BG O and B) and those who did not receive CP containing anti-A Ab (BG A and AB). Results: Among the 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7) and 15 patients did not receive anti-A Ab CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate, and the discharge rate were lower in patients who received CP containing anti-A Ab than not containing anti-A Ab CP. However, only the difference in the rate of MV support achieved statistically significance (P = 0.04) Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody’s ability to block the ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers.Key words: Blood groups, COVID-19, convalescent plasma

PDF

___

1. Li Q, Guan X, Wu P, Wang X, Zhou L et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus infected pneumonia. New England Journal of Medicine 2020; 382 (13): 1199-1207. doi: 10.1056/NEJMoa2001316
2. Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel Coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine 2020; 382 (8): 727-733. doi: 10.1056/NEJMoa2001017
3. Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. Journal of Antimicrobial Chemotherapy 2005; 56 (5): 919-922. doi: 10.1093/jac/dki346
4. Ko JH, Seok H, Cho SY, Ha YE, Baek JY et al. Challenges of convalescen plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral Therapy 2018; 23 (7): 617-622. doi: 10.3851/IMP3243
5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of Virology 2020; 94(7): e00127-20.doi:10.1128/JVI.00127-20
6. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-292.e6. doi:10.1016/j. cell.2020.02.058
7. Lu R, Zhao X, Li J, Niu P, Yang B et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–574. doi:10.1016/S01406736(20)30251- 8
8. Guillon P, Clement M, Sebille V, Rivain JG, Chou CF et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by antihisto-blood group antibodies. Glycobiology 2008; 18(12): 1085-1093. doi:10.1093/ glycob/cwn093
9. Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and 206 antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus Disease 2020; 31(1): 13-21. doi:10.1007/ s13337-020-00571-5
10. Batool Z, Durrani SH, Tariq S. Association of ABO and Rh blood group types to hepatitis B, hepatitis C, Hiv And Syphilis infection, a five year’ experience in healthy blood donors in a tertiary care hospital. Journal of Ayub Medical College, Abbottabad 2017; 29 (1): 90-92.
11. Arendrup M, Hansen JE, Clausen H, Nielsen C, Mathiesen LR et al. Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS 1991; 5 (4): 441-444. doi: 10.1097/00002030-199104000-00014
12. Preece AF, Strahan KM, Devitt J, Yamamoto FF, Gustavson K. Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood 2002; 99 (7): 2477-2482. doi: 10.1182/blood.v99.7.2477
13. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK et al. ABO blood group and susceptibility to severe acute respiratory syndrome. The Journal of the American Medical Association 2005; 293 (12): 1450-1451. doi: 10.1001/jama.293.12.1450-c
14. Chen J, Subbarao K. The immunobiology of SARS. Annual Review of Immunology 2007; 25: 443-472. doi: 10.1146/ annurev.immunol.25.022106.141706
15. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. American Journal of Pathology 2007; 170 (4): 1136-1147. doi: 10.2353/ajpath.2007.061088
16. Turk C, Turk S, Temirci ES, Malkan UY, Haznedaroglu İC. In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus. Journal of the Renin-Angiotensin-Aldosterone System 2020; 21 (2). doi: 10.1177/1470320320928872
17. Neil SJ, McKnight A, Gustafsson K, Weiss RA. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood 2005; 105 (12): 4693-4699. doi: 10.1182/blood-2004-11-4267
18. Li J, Wang X, Chen J, Cai Y, Deng A et al. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. British Journal of Haematology 2020; 190 (1): 24-27. doi: 10.1111/bjh.16797
19. Tendulkar AA, Jain PA, Velaye S. Antibody titers in Group O platelet donors. Asian Journal of Transfusion Science 2017; 11 (1): 22-27. doi: 10.4103/0973-6247.200765
20. De França NDG, Poli MCC, Ramos PGdA, Borsoi CSdR, Colella R. Titers of ABO antibodies in group O blood donors. Revista Brasileira de Hematologia e Hemoterapia 2011; 33 (4): 259-262. doi: 10.5581/1516-8484.20110073
21. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69 (6): 1691-1695.
22. O’Sullivan JM, Ward S, Fogarty H, O’Donnell JS. More on “association between ABO blood groups and risk of SARSCoV-2 pneumonia”. British Journal of Haematology 2020; 190 (1): 27-28. doi: 10.1111/bjh.16845
23. Focosi D. Anti-A isohemagglutinin titers and SARS-CoV2 neutralization: implications for children and convalescent plasma selection. British Journal of Haematology 2020; 190 (3): e148-e150. doi: 10.1111/bjh.16932